Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Simplified HCV Integrated Management Model in Methadone Clinics in Ukraine (SHIM)

12. september 2026 oppdatert av: Ukrainian Institute on Public Health Policy

The goal of this pragmatic, quasi-experimental cluster trial is to evaluate whether simplified, onsite hepatitis C virus (HCV) treatment integrated into opioid agonist maintenance therapy (OAMT) clinics improves cure rates compared with referral-based care in Ukraine . The study includes adults (18 years and older) receiving OAMT with confirmed chronic HCV infection and no prior HCV treatment.

The main questions it aims to answer are:

  • Does onsite Simplified HCV Integrated Management (SHIM) increase the proportion of patients achieving sustained virologic response 12 weeks after treatment completion (SVR12) compared with case management and referral (CMR) to specialist clinics?
  • Does adding provider pay-for-performance (P4P) incentives to SHIM further improve progression along the HCV treatment cascade and SVR12 rates?

Researchers compared three models of care across 13 OAMT clinics in 12 Ukrainian cities:

  • Case Management and Referral (CMR): structured referral to off-site specialist clinics for HCV treatment
  • SHIM: simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
  • SHIM + P4P: SHIM with provider incentives linked to completion of key cascade milestones All SHIM clinics were supported by Project ECHO telementoring to strengthen clinician capacity . The study used nationally procured direct-acting antivirals (DAAs) under routine program conditions and did not reimburse diagnostic costs.

Between February 2023 and December 2024, 616 eligible patients were enrolled .

Participants:

  • Completed confirmatory HCV RNA testing
  • Underwent simplified pretreatment clinical and laboratory assessment
  • Received 12 weeks of pan-genotypic DAA treatment either onsite (SHIM arms) or at specialist clinics (CMR arm)
  • Attended follow-up visits during treatment for adherence assessment and counseling
  • Were prescribed HCV RNA testing 12 weeks after treatment completion to confirm cure (SVR12) The primary outcome was SVR12. Secondary outcomes included completion of pretreatment evaluation, treatment initiation, treatment completion, and completion of SVR assessment.

This study evaluates HCV care under real-world conditions during ongoing national treatment scale-up in Ukraine. The findings inform whether integrating simplified HCV treatment into OAMT clinics-and aligning provider incentives-can improve cure rates and accelerate progress toward HCV elimination in high-burden populations.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

616

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Kyiv, Ukraina, 01054
        • Ukrainian Institute on Public Health Policy

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • currently receiving treatment at the selected OAT site (implying a diagnosis of opioid dependence according to ICD 10);
  • aged 18 years or older;
  • residing within the study catchment area; and
  • having a positive HCV antibody test documented in the medical chart

Exclusion Criteria:

  • previous HCV treatment history;
  • active tuberculosis (assessed using 4-item screening questionnaire and confirmed according to the current national protocol);
  • pregnant or planning pregnancy in the next 6 months;
  • planning to move to another city in the next 6 months;
  • unwillingness to undergo confirmatory HCV RNA PCR test at their own expense and treat HCV

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Helsetjenesteforskning
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Case Management and Referral
structured referral to off-site specialist clinics for HCV treatment
structured referral to off-site specialist clinics for HCV treatment
Eksperimentell: Simplified HCV Integrated Management
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
Eksperimentell: Simplified HCV Integrated Management + Pay-for-performance
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians with provider incentives linked to completion of key cascade milestones
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
provider incentives linked to completion of key cascade milestones

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sustained virologic response
Tidsramme: Up to 24 weeks after treatment completion
Number of participants who have HCV RNA below the limit of quantitation (≤50 IU/mL) based on clinical records
Up to 24 weeks after treatment completion

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Completion of all pretreatment diagnostic assessments
Tidsramme: Through study completion, an average of 2 weeks after baseline
Number of participants who complete all pretreatment diagnostic assessments according to the SHIM algorithm (complete blood count, basic metabolic panel (including creatinine), hepatic function panel, fibrosis assessment, and HBsAg testing) based on clinical records
Through study completion, an average of 2 weeks after baseline
Treatment initiation
Tidsramme: Through study completion, an average of 4 weeks after baseline
Number of participants who are prescribed treatment for HCV infection based on clinical records
Through study completion, an average of 4 weeks after baseline
Treatment completion
Tidsramme: Through study completion, an average of 14 weeks after baseline
Number of participants who complete the full course of HCV treatment as prescribed based on clinical records
Through study completion, an average of 14 weeks after baseline
SVR assessment completion
Tidsramme: Up to 24 weeks after treatment completion
Number of participants who complete HCV RNA testing for SVR confirmation based on clinical records
Up to 24 weeks after treatment completion
HCV reinfection
Tidsramme: 12 months after treatment completion
Number of participants who receive a positive result of HCV RNA test at 12 months after treatment completion, based on clinical records
12 months after treatment completion

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. mars 2023

Primær fullføring (Faktiske)

31. oktober 2025

Studiet fullført (Faktiske)

31. desember 2025

Datoer for studieregistrering

Først innsendt

27. februar 2026

Først innsendt som oppfylte QC-kriteriene

28. april 2026

Først lagt ut (Faktiske)

6. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-delingstidsramme

January 1, 2026 - June 30, 2029

Tilgangskriterier for IPD-deling

Reasonable request to the principal investigator

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ICF

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere